CORXEL Gets CDE Green Light for Phase III Aficamten Study in nHCM
CORXEL, formerly known as Ji Xing Pharmaceuticals, a China-based pharmaceutical company, has announced that it...
CVD
FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind
The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...
Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...
Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters
Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...
Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...
Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...
Viatris Secures Late-Stage Programs from Idorsia with Potential for Future Asset Additions
US pharmaceutical company Viatris (NASDAQ: VTRS) has entered into a licensing agreement with Swiss drugmaker...
MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System
MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its...
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12%...
Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...
Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...
Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China
Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...
Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias
Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt...
Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...
China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...